Isoquercetin
- Generic Name
- Isoquercetin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20O12
- CAS Number
- 482-35-9
- Unique Ingredient Identifier
- 6HN2PC637T
- Background
Isoquercetin has been used in trials studying the treatment of Kidney Cancer, Renal cell carcinoma, Advanced Renal Cell Carcinoma, Thromboembolism of Vein in Pancreatic Cancer, and Thromboembolism of Vein VTE in Colorectal Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Nepal Health Research Council
- Target Recruit Count
- 250
- Registration Number
- NCT04733651
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- AB Science
- Target Recruit Count
- 200
- Registration Number
- NCT04622865
- Locations
- ๐ซ๐ท
Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France
๐ซ๐ทCHU Clermont-Ferrand: Site Gabriel-Montpied, Clermont-Ferrand, France
๐ซ๐ทLe Tripode, Groupe hospitalier Pellegrin CHU de Bordeaux, Bordeaux, France
Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2024-01-02
- Target Recruit Count
- 46
- Registration Number
- NCT04514510
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Isoquercetin in Sickle Cell Anemia
- Conditions
- Interventions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Jeffrey Zwicker, MD
- Registration Number
- NCT04474626
Impact of isoQUercetin and Aspirin on Platelet Function
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- University of Reading
- Registration Number
- NCT02866448
- Locations
- ๐ฌ๐ง
University of Reading, Reading, Berkshire, United Kingdom
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
- Conditions
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 104
- Registration Number
- NCT02446795
- Locations
- ๐ฎ๐น
Ospedale Oncologico Regionale - Centro di Riferimento Oncologico di Basilicata U.O. di Oncologia Medica, Rionero in vulture, Potenza, Italy
๐ฎ๐นFondazione G. Pascale, Naples, Italy
๐ฎ๐นUniversity Federico II of Naples, Naples, Italy
Cancer Associated Thrombosis and Isoquercetin (CATIQ)
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Jeffrey Zwicker, MD
- Target Recruit Count
- 64
- Registration Number
- NCT02195232
- Locations
- ๐บ๐ธ
York Hospital-Oncology Treatment Center, York, Maine, United States
๐บ๐ธVA Connecticut Healthcare System, West Haven, Connecticut, United States
๐บ๐ธVeterans Affair Medical Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.